Towa Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4553.T

Towa Pharmaceutical Co., Ltd. Receivables for the year ending March 31, 2024: USD 473.44 M

Towa Pharmaceutical Co., Ltd. Receivables is USD 473.44 M for the year ending March 31, 2024, a 15.64% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Towa Pharmaceutical Co., Ltd. Receivables for the year ending March 31, 2023 was USD 409.41 M, a -1.80% change year over year.
Towa Pharmaceutical Co., Ltd. Receivables for the year ending March 31, 2022 was USD 416.89 M, a 0.84% change year over year.
Towa Pharmaceutical Co., Ltd. Receivables for the year ending March 31, 2021 was USD 413.43 M, a 6.95% change year over year.
Towa Pharmaceutical Co., Ltd. Receivables for the year ending March 31, 2020 was USD 386.58 M, a 23.97% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Tokyo Stock Exchange: 4553.T

Towa Pharmaceutical Co., Ltd.

CEO	Mr. Itsuro Yoshida
IPO Date	April 5, 2004
Location	Japan
Headquarters	2-11, Shinbashi-cho
Employees	4,588
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Personal Care

Description

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.

Key trends

Past 5 years